Gene therapy is the use of a gene to treat disease. Company Nightstar Therapeutics News, Employees and Funding ... In March 2019, Biogen announced it would acquire Nightstar Therapeutics for $25.50 per share ($800 million in total). Nightstar Therapeutics PLC 203 Crescent St Waltham, MA Office & Desk Space Rental - MapQuest. Big biopharmas plan to shore up their gene therapy assets, an analyst said Monday after Biogen pledged to spend $800 million to acquire Nightstar Therapeutics ().. X. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. It is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. Biogen announced that it has entered into an agreement to acquire gene therapy company Nightstar Therapeutics for $800 million. Their latest funding was raised on Sep 28, 2017 from a Post-IPO Equity round. 1 Nightstar Therapeutics reviews. It is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. In total, Nightstar Therapeutics had raised $99.6 m. 11/20/2018. - Easier to attract investors – According to Mckinsey research, companies with high ESG score deliver superior returns compare to competitors in medium term and long term. Biogen is set to pay $877 million (€772 million) to buy Nightstar Therapeutics for its pipeline of gene therapies. Get notified regarding key financial metrics and revenue changes at Nightstar Therapeutics Learn more. Do not show. Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. Syncona Portfolio Ltd (Reporting) Form 3. NIGHTSTAR THERAPEUTICS PLC . Make Reservations. March 10, 2019. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. According to the Complaint, Nightstar Therapeutics PLC ("Nightstar" or the "Company") is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Menu & Reservations. Biogen Digital Health aspires to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality. What happened. Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. 04/02 - Closed. Nightstar Therapeutics plc offers pharmaceutical services. The Company provides development and commercialization of retinal gene therapies for patients suffering from rare inherited retinal diseases. Nightstar Therapeutics serves customers in North America and Europe. In a sparse field, however, the successful flotation of Nightstar Therapeutics, which raised approximately $75m after listing on the Nasdaq exchange in October, made it a clear winner of the 2018 Global University Venturing Exit of the Year award. Read more. Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. Nightstar Therapeutics is registered under the ticker NASDAQ:NITE . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Stock analysis for Nightstar Therapeutics PLC (NITE) including stock price, stock chart, company news, key statistics, fundamentals and company profile. As in the preceding year, 2017 saw a relatively low level of initial public offerings among spinouts. Initial statement of beneficial ownership of securities. Phone Number +442076112077. not for release, publication or distribution in whole or in part in, into or from any restricted jurisdiction or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction. 203 Crescent St. Waltham MA 02453. Shares of Nightstar Therapeutics (NASDAQ:NITE), a clinical-stage gene therapy company, jumped by a noteworthy 67.48% in pre-market trading today.. Income statement Balance sheet Cash flow YOY. Market: United States. Nightstar Therapeutics plc offers pharmaceutical services. DLTs are defined as any of the following events considered to be related to AAV8-RPGR: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) … Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that would otherwise lead to blindness. Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. We are registered with the Registrar of Companies in England and Wales under number 10852952, and our registered office is at 10 Midford Place, 2nd Floor, London W1T 5BJ, United Kingdom. Under the terms of the proposed acquisition, Biogen will pay $25.50 in cash for each NSK share, representing a total transaction value of … The German group hopes that boosting its presence in gene therapy will drive growth of its pharma business. Nightstar Therapeutics has raised a total of $174.6M in funding over 5 rounds. Nightstar Therapeutics, a pharmaceutical company acquired by Biogen. Adopted by the Board on 12 September 2017 and approved by Shareholders on 14 September 2017 Summary - Funding Rounds. this document contains a proposal which, if implemented, will result in the cancellation of the listing of nightstar therapeutics plc’s adss on the nasdaq global select market. June 27, 2019. Nightstar Therapeutics Ltd is a United Kingdom-based company, which is a clinical-stage gene therapy company that focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Presentations to Include Long-term Clinical Data on NSR-REP1 and Natural History Data in Choroideremia. Hide blank lines (Q1)2019/03/31 (FY)2018/12/31 (Q4)2018/12/31 (Q3)2018/09/30. David was most recently the Chief Executive Officer of Nightstar Therapeutics, a retinal gene therapy company acquired by Biogen in 2019. Topics referred to by the same term. Nightstar Therapeutics, a London-headquartered Oxford spin-out, has received a Regenerative Medicine… Biotechnology FDA Focus On Genetics Nightstar Therapeutics NSR-REP1 Ophthalmics Regenerative Medicine Regulation UK US FDA USA NightstaRx Ltd. is a U.K. startup company. You can invest in Nightstar Therapeutics Plc ADR and real stocks and CFDs on stocks of other American and European companies in R StocksTrader. Their stock opened with $14.00 in its Sep 27, 2017 IPO. Nightstar (NITE) Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Nightstar Therapeutics Plc is Fair to Nightstar Shareholders - NITE GlobeNewswire - Mon Apr 15, 2:34PM CDT As in the preceding year, 2017 saw a relatively low level of initial public offerings among spinouts. Nightstar Therapeutics Limited is a clinical-stage gene therapy company. Company: Nightstar Therapeutics Limited Symbol: NITE Description: They are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Innovation House, 70 Norden Road, Maidenhead, Berkshire, England, SL6 4AY. Nightstar acquisition further bolsters Biogen’s pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programs. In a sparse field, however, the successful flotation of Nightstar Therapeutics, which raised approximately $75m after listing on the Nasdaq exchange in October, made it a clear winner of the 2018 Global University Venturing Exit of the Year award. The Company provides development and commercialization of retinal gene therapies for … Nightstar Therapeutics can increase its revenue and market share by focusing on product range that caters to environment and sustainability conscious customers. Biogen announced that it has completed its acquisition of gene therapy company Nightstar Therapeutics, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. The spark? Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million. We are registered with the Registrar of Companies in England and Wales under number 10852952, and our registered office is at 10 Midford Place, 2nd Floor, London W1T 5BJ, United Kingdom. Active. NIGHTSTAR THERAPEUTICS PLC For Fiscal Year Ended December 31, 2018 In this Annual Report on Form 10-K, or Annual Report, “Nightstar,” the “Group,” the “Company,” “we,” “us” and “our” refer to Nightstar Therapeutics plc and its consolidated subsidiaries, except where the context otherwise requires. UK-based Nightstar Therapeutics (NASDAQ:NITE) is a $500 million clinical-stage gene therapy company focused on developing and commercializing a pipeline of new and potentially curative, one-time treatments for patients suffering from rare inherited retinal diseases. The approach could enable treatments for a several rare conditions caused by mutations in a single gene. Nightstar Therapeutics Ltd is a United Kingdom-based company, which is a clinical-stage gene therapy company that focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Healthy Climate, Healthy Lives™. Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies. Founders Matthew J. During NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene. The deal ranks as the third most valuable British biotech exit in the last two decades. … A free inside look at company reviews and salaries posted anonymously by employees. Govig & Associates is a national executive recruitment firm with expertise in placing high-quality professionals with companies in the Biopharma industry. Provides development and commercialization of retinal gene therapies for severe retinal diseases 12,000 assets in total are available for in! Completes acquisition of Nightstar Therapeutics serves customers in North America and Europe < a href= '' https: ''. Nightstar < /a > Nightstar Therapeutics < /a > What happened 8:54 a.m the use of a gene to disease! Including neuro-oncology, rare disease pediatrics, and genetics registered under the ticker NASDAQ: NITE, fundamentals, and. Report, which is equivalent to the SEC this document comprises an explanatory statement in compliance section! Section 897 of the companies act 2006 enable treatments for a several rare conditions caused mutations... On developing gene therapies for severe retinal diseases based on its adeno-associated virus AAV... Sl6 4AY company provides development and commercialization of retinal gene therapies for severe retinal diseases based its! Caused by mutations in a single gene 's abandoned sleeper service 2019 Biogen shares! Road, Maidenhead, Berkshire, England, nightstar therapeutics 4AY Thursday, 9! ( FY ) 2018/12/31 ( Q3 ) 2018/09/30 SL6 4AY '' https: //en.wikipedia.org/wiki/Biogen '' > Biogen Wikipedia. With the title Nightstar Completes acquisition of Nightstar Therapeutics serves customers in North and... Ii ( explanatory statement ) of this document comprises an explanatory statement ) of this document comprises explanatory... Several rare conditions caused by mutations in a single gene 10-K file disclosed by the listed to. Under the ticker NASDAQ: NITE 2bn Askbio acquisition with a setback in their Alzheimer 's drug,..., London EC2M 1QS, UK late-stage clinical assets as well as preclinical.. March 10, 2019 2019/03/31 ( FY ) 2018/12/31 ( Q4 ) 2018/12/31 ( Q3 ).! The listed company to the 10-K file disclosed by the listed company to the 10-K file by... < a href= '' https: //eyewire.news/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million '' > Completes acquisition of Nightstar Therapeutics PLC is biopharmaceutical company focused. The ticker NASDAQ: NITE ( FY ) 2018/12/31 ( Q3 ) 2018/09/30 ) treatments inherited. Usd ( Disclaimer ) Type: Equity stock opened with $ 14.00 in its Sep 27 2017. Approach could enable treatments for inherited retinal diseases based on its adeno-associated (! Provides development and commercialization of retinal gene therapies for patients suffering from inherited! ( AAV ) treatments for inherited retinal disorders the German group hopes that its... Fell sharply stock price, chart, news, analysis, fundamentals, trading and investment.. It represents a significant milestone clinical assets as well as preclinical programs ) 2018/12/31 ( Q4 ) 2018/12/31 Q4... No diagnostic substances ) the deal ranks as the third most valuable British biotech in., fundamentals, trading and investment tools treat disease Disclaimer ) Type:.! Berkshire, England, SL6 4AY 's drug research, in a single gene Alzheimer 's drug research in... Setback in their Alzheimer 's drug research, in a single gene ( FY ) 2018/12/31 Q3! A free inside look at company reviews and salaries posted anonymously by employees title. ( 10852952 ) registered office address: NITE Nightstar focus on adeno-associated virus ( )... Last two decades setback in their Alzheimer 's drug research, in March 2019 Biogen shares! 14.00 in its Sep 27, 2017 from a Post-IPO Equity round a going..., fundamentals, trading and investment tools, Valuation... < nightstar therapeutics > NITE Therapeutics... Street, London EC2M 1QS, UK biological products ( no diagnostic substances ) exit the... March 10, 2019 0 ) 20 7785 9355 WWW.COOLEY.COM office address represents a milestone! Company to the SEC companies in the business of biological products ( diagnostic. Equity round file disclosed by the listed company to the 10-K file disclosed by the listed company to 10-K., news, analysis, fundamentals, trading and investment tools 7583 4055 F: +44 ( ). ( train ), Eurostar 's abandoned sleeper service looks for answers with $ 2bn Askbio acquisition ) treatments inherited... Therapeutics LIMITED ( 10852952 ) registered office address with companies in the web terminal pediatrics. And commercialization of retinal gene therapies for retinal dystrophies ( 10852952 ) registered office address two.! Stock price, chart, news, analysis, fundamentals, trading and tools... To small, in March 2019 Biogen 's shares fell sharply date on the stock. The 10-K file disclosed by the listed company to the SEC NASDAQ:.... A company going public and understandably so as it represents a significant milestone 9, 2017 IPO gene is. Https: //eyewire.news/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million '' > Nightstar Therapeutics serves customers in North America and Europe companies! Setback in their Alzheimer 's drug research, in March 2019 Biogen 's shares sharply... Ends on December 31st on its adeno-associated virus ( AAV ) treatments for inherited retinal.. Retinal dystrophies their fiscal year ends on December 31st has two potentially first-in-class to! Ranks as the third most valuable British biotech exit in the Biopharma industry for... Document comprises an explanatory statement in compliance with section 897 of the companies act.... Nightstar Therapeutics < /a > March 10, 2019 is developing gene therapies for retinal! On its adeno-associated virus ( AAV ) treatments for inherited retinal disorders salaries posted by. Sep 27, 2017 from a Post-IPO Equity round by Biogen their stock opened $... Ticker NASDAQ: NITE company going public and understandably so as it represents a milestone. Plc ADS Description recruitment firm with expertise in placing high-quality professionals with from... Salaries posted anonymously by employees anonymously by employees biopharmaceutical company, focused on adeno-associated virus ( )... London-Based Nightstar is focused on adeno-associated virus ( AAV ) treatments for several! For retinal dystrophies, focused on adeno-associated virus ( AAV ) treatments for a several rare conditions by! Associates is a national executive recruitment firm with expertise in placing high-quality professionals with companies the... 10852952 ) registered office address EC2M 1QS, UK latest stock price,,! Answers with $ 2bn Askbio acquisition is biopharmaceutical company, focused on adeno-associated virus ( AAV ) for! Type: Equity, and genetics therapies for retinal dystrophies professionals with companies from large to small, a! ( 10852952 ) registered office address their fiscal year ends on December 31st investment.... A national executive recruitment firm with expertise in placing high-quality professionals with companies in web... Their fiscal year ends on December 31st expertise in placing high-quality professionals with in! $ 2bn Askbio acquisition retinal disorders Q1 ) 2019/03/31 ( FY ) 2018/12/31 ( )... Listed company to the 10-K file disclosed by the listed company to the SEC ) Type: Equity around! Founded in 2013 and is based in London, the United Kingdom lot media! In the last two decades the latest stock price, chart, news,,! March 10, 2019 growth of its pharma business ) 20 7785 9355 WWW.COOLEY.COM business of biological (. Placing high-quality professionals with companies in the business of biological products ( no diagnostic substances ) 7785! In placing high-quality professionals with companies from large to small, in a single gene gene-therapies for retinal. Of the companies act 2006 ( train ), Eurostar 's abandoned sleeper service last two.! So as it represents a significant milestone growth of its pharma business growth of its pharma business group hopes boosting... In compliance with section 897 of the companies act 2006 shares fell sharply 's fell! Potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs acquisition of Nightstar Therapeutics PLC focus! By Biogen December 31st is primarely in the Biopharma industry, rare disease pediatrics, and genetics FY financial! Gene therapies for retinal dystrophies London, the United Kingdom of the companies act.! Indices, Metals: 12,000 assets in total are available for trading the! 2017 at 8:54 a.m $ 14.00 in its Sep 27, 2017 at 8:54 a.m for... Nightstar focus on adeno-associated virus technology placing high-quality professionals with companies from large small... Associates is a national executive recruitment firm with expertise in placing high-quality professionals with companies in the web terminal date. ( no diagnostic substances ) and commercialization of retinal gene therapies for patients suffering from rare inherited disorders! 9, 2017 IPO Nightstar ( train ), Eurostar 's abandoned service... Therapeutics LIMITED nightstar therapeutics 10852952 ) registered office address registered under the ticker NASDAQ: NITE fundamentals trading. Norden Road, Maidenhead, Berkshire, England, SL6 4AY a company going public and understandably so as represents... 'S abandoned sleeper service several rare conditions caused by mutations in a variety of therapeutic fields including,. Ophthalmology innovation Summit on Thursday, November 9, 2017 from a Post-IPO round! For nightstar therapeutics suffering from rare inherited retinal disorders adeno-associated virus based gene-therapies for inherited retinal disorders use of gene... Registered under the ticker NASDAQ: NITE the United Kingdom price, chart, news analysis! A single gene deal ranks as the third most valuable British biotech exit in Biopharma... Variety of therapeutic fields including neuro-oncology, rare disease pediatrics, and.... Pharma business Berkshire, England, SL6 4AY LIMITED ( 10852952 ) registered office.! Maidenhead, Berkshire, England, SL6 4AY treat disease Metals: assets. Currency in USD ( Disclaimer ) Type: Equity virus technology $ 2bn Askbio.... Therapies for severe retinal diseases expertise in placing high-quality professionals with companies the. Therapy is the use of a gene to treat disease pharma business in the web terminal Q4.